Natco Pharma logs highest-ever sales, net in FY25, wary of headwinds for U.S. business in FY26
The Hindu
Natco Pharma anticipates revenue and profit decline in FY26 due to geopolitical uncertainties and increased R&D expenses.
Natco Pharma estimates a possible dip in revenue by 20% and profit by as much 30% in FY26 due to geopolitical uncertainties and pricing pressure in its core product portfolio in the U.S. and on account of increased research and development (R&D) expenses.
On the back of a strong cash position of over ₹3,000 crore as of March 31, 2025, it is preparing for headwinds coming from its U.S. business during the current fiscal. The Hyderabad-based generic drugmaker said this announcing consolidated net profit for 2024-25 at ₹1,883.4 crore and total revenue of ₹4,784 crore were the highest thus far.
The financial performance last fiscal was “result of decades of our diligence,” Natco Pharma. While net profit was an increase of 36% compared to ₹1,388.3 crore in 2023-24, total revenue was 16% higher from ₹4,126.9 crore year earlier.
https://www.thehindu.com/business/front-end-manufacturing-in-us-way-forward-to-counter-tariff-impact-on-pharma-natco-pharma-ceo/article69243853.ece
The guidance for the current fiscal comes after vice-chairman and CEO Rajeev Nannapaneni in February this year told investors, in the backdrop of U.S. threatening high tariffs on pharma imports, about the need for a front-end manufacturing in the U.S. That’s the only way you can go forward. Appears to be the only solution, he had said.
For the quarter ended March, the company posted 5% higher net profit at ₹406 crore (₹386.3 crore) on a nearly 16% increase to ₹1,287.3 crore (₹1,110.3 crore).
During the quarter, the company took an impairment charge of ₹50 crore in the Crop Health Science business related to property, plant and machinery, a chargeback adjustment of approximately ₹25 crore in its U.S. subsidiary apart from higher R&D expenses.
Premiumisation is driving the growth in beauty and personal care industry in India and this segment is growing faster than the products made for the masses, industry executives said at Cosmoprof India 2025, a beauty & personal care industry event currently underway in Mumbai.
Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.
The Rupee appreciated by 19 paise to close at 89.96 against the U.S. dollar amid weak dollar index support.
India aims to expand its tea exports to China, highlighting diverse varieties like Darjeeling and Masala at a recent buyer-seller meet.
Stock markets rebound after four days of decline as Sensex rises 158 points, driven by tech and IT shares.
India reduces Russian oil imports by 38% in October 2025, marking the sharpest decline in value and volume yet.
Suzlon announces three new AI-enabled smart blade factories, expanding its manufacturing footprint to 20 facilities in India.
Odisha Government terminates Silicon Tech Lab's empanelment for involvement in a recruitment scam and service agreement violations.
Worli, Mumbai, dominates India’s ultra-luxury apartment market, accounting for 40% of transactions worth ₹5,500 crore in two years.
IndiGo faces disruptions due to a hiring freeze, prompting pilots' body to urge regulatory intervention for safe operations.
Nvidia CEO Jensen Huang met separately with U.S. President Donald Trump and Republican senators Wednesday
Rupee falls to 90.43 against the dollar amid RBI's restrained intervention and high importer demand, causing market concerns.
Meta’s poaching of Apple's Alan Dye underscores its push to expand consumer hardware beyond its smart glasses